Bayer's Eylea declines by 24%, bearing the brunt of biosmilar competition

12th May 2026 Uncategorised 0

After staving off significant sales declines for Eylea, Bayer is getting hit with full force by biosimilar competition for the eye disease treatment, which saw a 24% sales decline in the first quarter.

More: Bayer's Eylea declines by 24%, bearing the brunt of biosmilar competition
Source: fierce